# Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB)

> **NCT06823401** · — · RECRUITING · sponsor: **Fondazione Ricerca Traslazionale** · enrollment: 270 (estimated)

## Conditions studied

- NSCLC

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06823401
- **Lead sponsor:** Fondazione Ricerca Traslazionale
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-20
- **Primary completion:** 2027-09-10
- **Final completion:** 2029-12-31
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06823401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06823401, "Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06823401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*